Substituted pyrazoles as p38 kinase inhibitors

US6979686B1 · kind B1 · utility

Assignee

• Pharmacia Corporation · SE

Inventors

• Ashok S. Naraian · Ballwin, US
• Michael Clare · Skokie, US
• Paul W. Collins · Deerfield, US
• Joyce Z. Crich · Glenview, US
• Rajesh Devraj · Chesterfield, US
• Daniel L. Flynn · Lawrence, US
• Lifeng Geng · Skokie, US
• Matthew J. Graneto · Chesterfield, US
• Cathleen Hanau · Chesterfield, US
• Gunnar J. Hanson · Cambridge, US
• Susan J. Hartmann · Kirkwood, US
• Michael Hepperle · Boston, US
• He Huang · Northbrook, US
• Francis J. Koszyk · Prospect Heights, US
• Shuyuan Liao · Northbrook, US
• Suzanne Metz · Chesterfield, US
• Richard A. Partis · Evanston, US
• Thao Perry · San Jose, US
• Shashidhar N. Rao · Chesterfield, US
• Shaun Raj Selness · Chesterfield, US
• Michael S. South · Chesterfield, US
• Michael A. Stealey · Libertyville, US
• John J. Talley · Chesterfield, US
• Michael L. Vazquez · Saint Louis, US
• Richard M. Weier · Lake Bluff, US
• Xiangdong Xu · Gurnee, US
• Ish Khanna · Vernon Hills, US
• Yi Yu · Skokie, US
• Win Naing · Chesterfield, US
• John Walker · Maryland Heights, US

Key dates

• Filing date: Dec 7, 2001
• Grant date: Dec 27, 2005
• Expiry date: May 28, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R1, R2, R3 and R4 are as described in the specification.